Sign In
Buy SHIEF
$0.0800
+0 (+0%)
At Close: Jun 02, 2026
Shield Therapeutics takes bold approach in the US
11:25am, Tuesday, 16'th Nov 2021
Evidence from clinical studies shows it provides long-term treatment for maintaining the body's iron stores. In our view, these factors provide a solid support for negotiating attractive deal terms.
Shield Therapeutics building a solid brand base says new Proactive research
11:04am, Tuesday, 16'th Nov 2021
Proactive Research has published a new note on Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) ahead of the launch of iron deficiency drug Accrufer in the US. In Europe, the drug is branded as Ferracru
Shield Therapeutics building a solid base says new Proactive research note
11:03am, Tuesday, 16'th Nov 2021
Proactive Research has published a new note on Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) ahead of the launch of iron deficiency drug Accrufer in the US. In Europe, the drug is branded as Ferracru
Shield Therapeutics takes bold approach in the US
06:15am, Monday, 27'th Sep 2021
Evidence from clinical studies shows it provides long-term treatment for maintaining the body's iron stores. In our view, these factors provide a solid support for negotiating attractive deal terms.
Shield Therapeutics names Jose A. Menoyo as chief medical officer
06:13am, Monday, 27'th Sep 2021
Shield Therapeutics PLC said Jose A. Menoyo, M.D.
Shield Therapeutics takes bold approach in the US
04:25am, Tuesday, 17'th Aug 2021
Evidence from clinical studies shows it provides long-term treatment for maintaining the body's iron stores. In our view, these factors provide a solid support for negotiating attractive deal terms.
Shield Therapeutics pleased with progress to date on US launch of Accrufer
04:24am, Tuesday, 17'th Aug 2021
Shield Therapeutics PLC said in its half-year results that the focus in the second half will be on the roll-out of Accrufer in the US. The product was launched in the US on 1 July, so the only impact
Shield Therapeutics higher after securing licence agreement in South Korea
09:40am, Thursday, 12'th Aug 2021
Shield Therapeutics PLC added 5% to 50p in the early afternoon after securing a licence agreement in South Korea for its Accrufer iron deficiency therapy. Under the deal with Korea Pharma Co Ltd, the
Shield Therapeutics surges as it inks licence agreement for Accrufer in South Korea
06:05am, Thursday, 12'th Aug 2021
Shield Therapeutics PLC (LSE:STX, FRA:1JS) shares surged on Thursday as it said it has secured a licence agreement in South Korea for its Accrufer iron deficiency therapy. Under the deal with Korea Ph
Shield Therapeutics inks licence agreement for Accrufer in South Korea
02:38am, Thursday, 12'th Aug 2021
Shield Therapeutics PLC said it has secured a licence agreement in South Korea for its Accrufer iron deficiency therapy. Under the deal with Korea Pharma Co Ltd, the company said it will receive an up
Shield Therapeutics appoints new CEO as it prepares for American launch of Accrufer
06:05am, Monday, 09'th Aug 2021
Evidence from clinical studies shows it provides long-term treatment for maintaining the body's iron stores. In our view, these factors provide a solid support for negotiating attractive deal terms.
Shield Therapeutics flags up academic article showcasing positive results from phase III trial
06:05am, Monday, 09'th Aug 2021
Shield Therapeutics PLC (LSE:STX, FRA:1JS) (LON:STX) has flagged up research in a leading academic publication showcasing some “very exciting” results from a study involving its lead product. Inve
Shield Therapeutics to launch Accrufer in US next week
03:43am, Thursday, 24'th Jun 2021
Shield Therapeutics PLC (LON:STX) confirmed it will launch its Accrufer product in the US on 1 July. The pharmaceutical company, which focuses on addressing iron deficiency, said launch stocks are cur
Shield Therapeutics appoints new CEO as it prepares for American launch of Accrufer
02:31am, Friday, 28'th May 2021
Evidence from clinical studies shows it provides long-term treatment for maintaining the body's iron stores. In our view, these factors provide a solid support for negotiating attractive deal terms.
Shield Therapeutics appoints CEO with "deep knowledge" of the iron deficiency market
02:30am, Friday, 28'th May 2021
Shield Therapeutics PLC (LON:STX) has appointed a new chief executive with “deep knowledge and previous experience in the US iron deficiency marketplace”. Greg Madison will take over on June 1 fro
